Details

Autor(en) / Beteiligte

• Shan, Jijun
• Jiang, Wangjie
• Chang, Jiang
• Zhou, Tao
• Chen, Yananlan
• Zhang, Yaodong
• Wang, Jifei
• Wang, Yuming
• Wang, Yirui
• Xu, Xiao
• Liu, Shuochen
• Shi, Xiaoli
• Fan, Shilong
• Chen, Ruixiang
• Li, Changxian
• Li, Xiangcheng

Titel

NUF2 Drives Cholangiocarcinoma Progression and Migration via Inhibiting Autophagic Degradation of TFR1

Ist Teil von

• International journal of biological sciences, 2023-01, Vol.19 (5), p.1336-1351

Ort / Verlag

Australia: Ivyspring International Publisher

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Cholangiocarcinoma (CCA) is the second most common primary hepatic malignancy and associated with poor prognosis. Lack of therapeutic methods for CCA and insensitivity of targeted therapy and immunotherapy make its treatment challenging. NUF2, a component of Ndc80 kinetochore complex, is implicated in the initiation and development of multiple cancers. However, the role and mechanism of NUF2 in CCA is still unclear. In this research, we investigated the biological processes and underlying mechanisms of NUF2 in CCA. We discovered that the expression of NUF2 was upregulated in CCA and negatively correlated with prognosis. Changes in NUF2 levels had an impact on cell proliferation and migration. Moreover, NUF2 functioned as an oncogene to promote the progression of CCA through p38/MAPK signaling by inhibiting p62 binding of TFR1 and affecting its autophagic degradation. In addition, TFR1 promoted CCA progression and Kaplan-Meier analyses uncovered patients with high expression of TFR1 was associated with the poor survival. In conclusion, our study demonstrated that NUF2 promoted CCA progression by regulating TFR1 protein degradation, and the NUF2/TFR1/MAPK axis could be an excellent therapeutic target for CCA.